3-Year Outcomes of XEN Implant Compared With Trabeculectomy, With or Without Phacoemulsification for Open Angle Glaucoma.
Marcos-Parra María Teresa, Mendoza-Moreira Angi Lizbeth, Moreno-Castro Lucía, Mateos-Marcos Carlos, Salinas-López Javier Alejandro, Figuerola-García María Belén, González-Alonso Ángela, Pérez-Santonja Juan José
AI Summary
This study compared XEN implants and trabeculectomy for glaucoma, finding trabeculectomy achieved greater IOP reduction and less needling over three years, guiding surgical choice.
Abstract
Prcis: Trabeculectomy (TRAB) surgery reduces the intraocular pressure (IOP) more than the XEN45 implant over 3 years. There is no difference in the number of antiglaucoma medications between the 2 procedures. The decision to perform either TRAB or XEN45 implantation must be evaluated on a case-by-case basis, taking into account the high rate of needling of the XEN45.
Purpose
The aim of this study was to compare the differences between the efficacy and safety of the XEN45 implant and TRAB, either alone or in combination with phacoemulsification (PHACO), in patients with open angle glaucoma (OAG) at 36 months.
Methods
A retrospective, single-center and comparative study conducted on OAG patients who underwent XEN45 implantation or TRAB from 2016 to 2018. Patients were divided into 4 groups: group 1 (XEN45 alone), group 2 (XEN45+PHACO), group 3 (TRAB alone), and group 4 (TRAB+PHACO). For statistical purposes, groups 1 and 2 were combined (XEN45 implant), whereas groups 3 and 4 were also combined (TRAB surgery). IOP, number of glaucoma medications, and adverse events were evaluated. The main outcome measure was the reduction in IOP at 36 months postoperatively.
Results
One hundred thirty-four patients (134 eyes; 63 XEN45 and 71 TRAB) were included. The mean (95% confidence interval) IOP reduction at the end of the study follow-up was -6.3 (-11.0 to -1.6 mm Hg, P =0.025, XEN45 alone), -8.9 (-11.0 to -6.8 mm Hg, P <0.001, TRAB alone), -2.5 (-4.5 to -0.4 mm Hg, P =0.019, XEN45+PHACO), and -5.6 (-7.7 to -3.4 mm Hg, P <0.001, TRAB±PHACO). The proportion of patients achieving an IOP≥6 and ≤16 mm Hg without treatment at the end of the 36-month follow-up were 50.8% (32/63) in the XEN45 implant and 49.3% (35/71) in the TRAB surgery group, P =0.863. The mean number of glaucoma medications was significantly reduced in all the study groups. The needling rate was 19% in XEN45 versus 5.6% in the TRAB group ( P =0.030), and 2.81% and 36.6% of eyes in the TRAB group presented anterior chamber flattening and hyphema, respectively.
Conclusions
TRAB surgery lowered IOP significantly more than XEN45 implant with or without phacoemulsification over 3 years and had a significantly lower need for additional needling surgery. Both procedures reduced glaucoma medications to a similar rate. These findings are relevant to the informed consent process and patient decisions for one procedure over the other.
MeSH Terms
Shields Classification
Key Concepts6
Trabeculectomy (TRAB) surgery reduced the intraocular pressure (IOP) more than the XEN45 implant over 3 years in patients with open angle glaucoma.
There was no significant difference in the number of antiglaucoma medications between the XEN45 implant and trabeculectomy (TRAB) procedures over 3 years in patients with open angle glaucoma (P =0.863).
The mean intraocular pressure (IOP) reduction at 36 months post-surgery for XEN45 alone was -6.3 mm Hg (95% confidence interval: -11.0 to -1.6 mm Hg, P =0.025) in patients with open angle glaucoma.
The mean intraocular pressure (IOP) reduction at 36 months post-surgery for trabeculectomy (TRAB) alone was -8.9 mm Hg (95% confidence interval: -11.0 to -6.8 mm Hg, P <0.001) in patients with open angle glaucoma.
The needling rate was 19% in the XEN45 implant group versus 5.6% in the trabeculectomy (TRAB) group (P =0.030) in patients with open angle glaucoma.
The proportion of patients achieving an intraocular pressure (IOP) between 6 and 16 mm Hg without treatment at 36 months was 50.8% (32/63) in the XEN45 implant group and 49.3% (35/71) in the trabeculectomy (TRAB) surgery group (P =0.863) for open angle glaucoma.
Related Articles5
Five-year outcomes of ab interno Xen 45 gel stent implantation.
Cohort StudyMid-term real world outcomes of the Hydrus ® Microstent in open angle glaucoma.
Case SeriesStandalone XEN45 Gel Stent implantation versus combined XEN45-phacoemulsification in the treatment of open angle glaucoma-a systematic review and meta-analysis.
Systematic ReviewComparing the Safety and Efficacy of Phacogoniosynechialysis With Phacotrabeculectomy in the Management of Refractory Acute Primary Closure Angle Glaucoma With Cataract: A Multicenter Randomized Trial.
Randomized Controlled TrialOutcomes of XEN45 gel stent using posterior small incision sub-tenon ab interno insertion (Semi-open) technique.
Case SeriesIs this article assigned to the wrong chapter(s)? Let us know.